GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Preliminary Phase II Results of Abiraterone Acetate in Patients with Castration-resistant metastatic Prostate Cancer after Failure of Docetaxel-based Chemotherapy
SAN FRANCISCO, CA (UroToday.com) - Dr. Danila, spoke about abiraterone acetate (AA), an oral and irreversible inhibitor of CYP17 that decreases testosterone and DHT levels to undetectable. The study presented sought to determine the proportion of patients achieving a PSA decline of >50% and to assess toxicity.
 | Written by Christopher P. Evans, MD, a Contributing Editor with UroToday. |
|
UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810
Privacy Policy | © 2009 UroToday ® All Rights Reserved |
